$INSY INSYS Therapeutics Inc. (NASDAQ: INSY) news: Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, was generally well-tolerated-even at high doses-as an investigational treatment for refractory pediatric epilepsy, according to new clinical data from a long-term safety study presented at the American Epilepsy Society (AES) 2018 annual meeting. "The results of this study support the promising safety profile of CBD oral solution from INSYS in the context of treating pediatric patients with intractable seizures due to epilepsy," said James W. Wheless, M.D., professor and chief of pediatric neurology at the University of Tennessee Health Science Center in Memphis, where he directs the Neuroscience Institute & Le Bonheur Comprehensive Epilepsy at Le Bonheur Children's Hospital and holds the Le Bonheur Chair in Pediatric Neurology. "In addition, these long-term safety data are consistent with those from other studies of CBD in refractory pediatric epilepsy."
Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.
